Life Sciences Deals, Growth, and the New M&A Market: EY's Subin Baral on What Comes Next

In this episode of BioTalk with Rich Bendis, Subin Baral, Partner at Ernst & Young LLP and EY-Parthenon Global Life Sciences Deals Leader, joins the conversation to discuss the changing life sciences dealmaking environment and what it means for companies, investors, and regional innovation ecosystems. Subin shares how life sciences companies are shifting from defensive portfolio management toward acquiring earlier-stage assets, technologies, and capabilities that can support long-term growth. He discusses why buyers are looking earlier in the development cycle, what makes an asset attractive in the current market, and why differentiated science, strong data, and flexible deal structures matter more than ever. The conversation also explores the current M&A environment, including EY's view that life sciences M&A activity has accelerated significantly, with stronger activity across both biopharma and MedTech. Subin touches on the broader mix of buyers entering the market, the role of mid-sized companies, and how areas such as oncology, immunology, neuroscience, cell and gene therapy, ADCs, bispecifics, AI, data, and quantum may shape future deal activity. Rich and Subin also discuss the growing role of China in global life sciences innovation, the challenges facing early-stage companies as funding remains difficult, and how startups can think about partnerships, capital access, and strategic flexibility in a more disciplined market. The episode also looks at what these trends mean for regions like the BioHealth Capital Region, including how emerging ecosystems can build visibility, strengthen networks, support differentiated technologies, and position companies for future capital, partnerships, and deal activity. Editing and post-production work for this episode was provided by The Podcast Consultant. Subin is a partner at Ernst & Young LLP and the EY-Parthenon Global Life Sciences Deals Leader. He has more than a decade of transaction experience, helping life sciences companies with transformational transactions. Subin has extensive global experience serving as a buy- and sell-side transaction advisor for Fortune 500 companies, including in corporate and private equity. His experience includes working with companies in the pharmaceutical, medical device and biotechnology subsectors. Subin focuses on acquisitions, carve-outs, spin-offs and initial public offerings and works with companies at all stages of maturity, from startups to public companies. He frequently speaks at life sciences events about sector trends and acquisitions and divestitures topics. He received his Master of Commerce from Macquarie University in Sydney, Australia. He is a chartered accountant from the Institute of Chartered Accountants of Australia and New Zealand.